✦ LIBER ✦

Phase II Study of Psychotherapeutic Intervention in Advanced Cancer

✍ Scribed by Marco J. De Vries; Johannes N. Schilder; Cornelis L. Mulder; Adriana M. E. Vrancken; Margot E. Remie; Bert Garssen

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 92 KB
Volume: 6
Category: Article
ISSN: 1057-9249
DOI: 10.1002/(sici)1099-1611(199706)6:2<129::aid-pon264>3.0.co;2-u

No coin nor oath required. For personal study only.

✦ Synopsis

The effect of psychosocial counseling on tumor progression was studied in 96 cancer patients, who were no longer amenable to regular medical treatment. Patients were offered 12 session of individual experiential-existential counseling, each sessions lasting 1.5 to 2 hours. In addition patients participated fortnightly in group counseling meetings. In five out of 35 evaluable patients, tumor growth became stationary during or immediately following therapy. In four patients this stationary period last 3-9 months, and in one patient 2 years. Natural Killer cell activity, self-reported loneliness, depression, purpose in life and locus of control showed no change from pre- to post intervention.

📜 SIMILAR VOLUMES

A phase II study of peptichemio in advan

A phase II study of peptichemio in advanced breast cancer

✍ V. Hug; G. N. Hortobagyi; A. U. Buzdar; G. R. Blumenschein; W. Grose; M. A. Burg 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 2 views

Phase I-II study of ftorafur and methyl-

Phase I-II study of ftorafur and methyl-ccnu in advanced colorectal cancer

✍ Robert J. Belt; Ronald Stephens 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 1 views

The combination of Ftorafur (NSC-148958) and methyl-CCNU (NSC-95441) was evaluated in 36 patients with advanced colorectal cancer. The principle toxicities encountered were myelosuppression, gastrointestinal, and neurological. There were no complete responses and only 5/34 (14.7%) patients achieved

Phase II study of doxorubicin plus ifosf

Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer

✍ Michael J. Millward; Adrian L. Harris; Brian M. J. Cantwell 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 429 KB

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced gastric cancer

✍ Kathy Christman; David Kelsen; Leonard Saltz; Peter G. Tarassoff 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

A phase II study of combined 5-fluoroura

A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer

✍ Willy Mattsson; Finn Von Eyben; Lennart Hallsten; Göran Bjelkengren 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views

In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c

A phase II study of piritrexim in patien

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

✍ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the